2024-10-17 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences Inc. is a biopharmaceutical company that develops and commercializes treatments for life-threatening diseases.

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** GILD: -11.19%, VOO: 135.94%.
* **Performance Gap:**  The current performance gap is -147.13%, indicating that GILD has significantly underperformed the S&P 500. 
* **Relative Performance Gap:** The relative performance gap is 5.45%, placing it within the 5.45% percentile of historical performance gaps.

**2. Recent Price Action:**

* **Closing Price:** $85.82
* **5-day Moving Average:** $85.40
* **20-day Moving Average:** $84.36
* **60-day Moving Average:** $79.50

The recent price action suggests a slight upward trend, with the closing price above all three moving averages.

**3. Technical Indicators:**

* **RSI:** 71.83 (Overbought)
* **PPO:** -0.2 (Negative)
* **Delta_Previous_Relative_Divergence:** -2.55 (Short-term downtrend)
* **Expected Return:** 0.0% (5-year expected return relative to the S&P 500)

The RSI suggests the stock is currently overbought, while the PPO indicates a slight bearish sentiment. The negative relative divergence suggests a potential for a short-term pullback.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | $6.95 B |
| 2024-05-08 | -3.34 | $6.69 B |
| 2023-11-07 | 1.75 | $7.05 B |
| 2023-08-04 | 0.84 | $6.60 B |
| 2024-08-08 | 0.84 | $6.60 B |

* The most recent earnings report for the quarter ending August 8th, 2024, showed an EPS of $1.29, exceeding analysts' expectations of $1.21. 
* Revenue came in at $6.95 billion, slightly above expectations.

**5. News and Recent Issues:**

* Gilead Sciences Inc. is expected to continue its focus on HIV and hepatitis C treatments, along with expanding its portfolio in oncology and cell therapy. 
* Recent news has focused on the company's efforts to develop new therapies for non-alcoholic steatohepatitis (NASH) and other emerging diseases.
* Analyst opinions on GILD remain mixed, with some analysts expecting the company to maintain a steady performance due to its strong portfolio and focus on innovation, while others are concerned about the potential for competition in key markets.

**6. Summary:**

Gilead Sciences Inc. has underperformed the S&P 500 significantly over the past period. However, recent earnings have been positive, and the company is focused on expanding its portfolio and developing new therapies. While the stock is currently overbought, the company's strong fundamentals suggest a potential for further growth in the long term.

**7. Key Takeaways:**

* GILD's performance has been lagging behind the market significantly.
* Recent earnings results have been positive and exceeded expectations.
* The company is focused on developing new therapies for emerging diseases and expanding its portfolio.
* The stock is currently overbought, but the strong fundamentals suggest potential for long-term growth.

**Disclaimer:** This report is for informational purposes only and should not be considered investment advice. It is crucial to conduct thorough research and consult with a financial advisor before making any investment decisions.